Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

August 1, 2019

Study Completion Date

March 1, 2020

Conditions
Breast Cancer
Interventions
DRUG

group (A)

patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.

DRUG

group (B)

patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.

DRUG

group (c)

patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.

Trial Locations (1)

171516

South Egypt Cancer Instuite, Asyut

All Listed Sponsors
lead

Assiut University

OTHER

NCT03165149 - Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding | Biotech Hunter | Biotech Hunter